Skip to content

FDA Approval of Breakthrough Therapy Designations Continue To Soar

April 29, 2014

The FDA announces April 29th, the approval of another FDA Breakthrough Therapy Designation (BTD). The accelerated approval is for Novartis’ orphan drug Zykadia (Ceritinib), previously known as LDK378, for patients with metastatic, Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC), who were previously treated with Pfizer’s orphan drug Xalkori (Crizotinib). Xalkori is the only other FDA approved (2011) ALK+ Tyrosine Kinase Inhibitor (TKI) for metastatic NSCLC.

Zykadia is the 4th drug with a BTD to receive FDA approval. The approval is 4 months ahead of the PDUFA date of August 24, 2014. The FDA granted Zykadia BTD, priority review, and orphan drug designation (September 2013).



FDA BTD Approval Chart

FDA BTD Statistics Chart.

Please Note: “Brown Pelican Soars (8425524047)” by Chris Hunkeler from Carlsbad, California, USA (Uploaded by High Contrast) [CC-BY-SA-2.0] | Wikimedia Commons..

Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: